Celgene Corporation (NASDAQ:CELG) is a $93-billion market cap pharmaceutical giant "focused on changing the course of human health through bold pursuits in science, life enhancing therapies and a promise to always put patients first," according to its website. First-quarter earnings reported April 2017 beat estimates by $0.05 per share with 18% revenue growth year-over-year. Its sales are led by blood oncology drug Revlimid (lenalidomide) with approximately 20% annual sales growth. Revlimid is expected to account for about 7 of 12 total billion in sales for CELG in 2017, as reported by JPMorgan (NYSE:JPM). The company is optimistic about Otezla expansion into Japanese markets. Two other drugs have even outperformed Revlimid, with three additional drugs contributing over a billion in sales each year. With forecasted earnings of more than $10 per share by 2020, one can see why CELG should be considered undervalued at $118 per share. The research pipeline at Celgene is impressive to say the least, with 28000 patients enrolled in clinical trials for more than 50 indications. Moreover, there is a lot of attention being gathered by the company regarding its pipeline expansion for 2017, with 19 phase 3 projects expected to be completed in the next two years.
